Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years
Authors:
- Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)P(Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
- Rebecca LodwickRLRebecca Lodwick
- Dominique CostagliolaDCDominique Costagliola
- Peter ReissPRPeter Reiss
- Carlo TortiCTCarlo Torti
- Ramón TeiraRTRamón Teira
- Maria DorrucciMDMaria Dorrucci
- Bruno LedergerberBLBruno Ledergerber
- Amanda MocroftAMAmanda Mocroft
- Daniel PodzamczerDPDaniel Podzamczer
- Alessandro Cozzi-LepriACAlessandro Cozzi-Lepri
- Niels ObelNONiels Obel
Open Access
- 8 March 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 170 (5) , 410-419
Abstract
Life expectancy and, equivalently, age-specific death rates in people with HIV have been estimated to be approaching those of the uninfected general population in some successfully treated subgroups.1,2 These promising life expectancies will only be realized, however, if death rates associated with HIV do not rise in the future. The main underlying mechanism by which rates have been reduced is complete suppression of viral replication by antiretroviral therapy (ART), and so low death rates are dependent on the duration of continued viral suppression. Most regimens used so far contain drugs from the original 3 ART classes: nucleos(t)ide reverse-transcriptase inhibitors (NRTIs), nonNRTIs (NNRTIs), and protease inhibitors (PIs). Current regimens tend to lead to sustained viral suppression in most patients, but rates of virologic failure (failure to [continue to] suppress viral load) remain appreciable. Virologic failure is thought to occur as the result of an uncertain mixture between suboptimal regimen adherence and the development of resistance. The fact that some patients are infected with resistant virus is probably an additional cause. So, while multiple drugs from several new classes are now available (integrase inhibitors, fusion inhibitors, and chemokine [C-C motif] receptor 5 [CCR5] antagonists), at least in high-income countries, lifelong viral suppression and consequential low death rates cannot be assured indefinitely. Virologic failure of the 3 original classes represents a key stage in a patient's drug failure history, and it is important to monitor the rate with which this is occurring to anticipate the continuing need for new drugs.3-12 Such prediction of future need is important in the light of the lengthy drug development process.Keywords
This publication has 28 references indexed in Scilit:
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort studyAIDS, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adultsHIV Medicine, 2008
- Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999HIV Medicine, 2008
- Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patientsAIDS, 2007
- Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status.Health Psychology, 2007
- Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort studyBMJ, 2005
- Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study GroupThe Journal of Infectious Diseases, 2004